Sevelamer May Have Benefits Beyond Phosphorus Lowering

Share this content:

This article is part of our ongoing coverage of Renal Week 2009. Click here for a complete list of our Renal Week Live articles.


Key Points

  • Sevelamer treatment for hyperphosphatemia in dialysis patients may provide benefits in addition to lowering phosphorus.
  • The sevelamer group experienced significant declines in total and low-density lipoprotein.
  • Serum uric acid decreased significantly in the sevelamer group, with the changes in uric acid levels parallel to serum phosphorus changes.

Sevelamer treatment for hyperphosphatemia in dialysis patients may provide benefits in addition to lowering phosphorus, according to a study conducted in Taiwan that was presented at ASN's Renal Week 2009.

In an eight-week open label study, researchers randomized 52 dialysis patients with hyperphosphatemia to receive either sevelamer or calcium acetate.

At the end of the study, the changes in serum phosphorus and adjusted serum calcium levels were similar for the two groups, but the calcium acetate group had more hypercalcemic events (12% vs. 3.7%).

The sevelamer group experienced significant declines in total and low-density lipoprotein (LDL). Total and LDL cholesterol correlated with changes in serum phosphate during sevelamer treatment.

Additionally, serum uric acid decreased significantly in the sevelamer group, with the changes in uric acid levels parallel to serum phosphorus changes, according to the investigators.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters